



8th European Forum on Hypertension

GDANSK, April 25-27, 2024

Holiday Inn Gdansk – City Centre, ul. Chmielna 1, Gdańsk, Poland

> Prof. Krzysztof Narkiewicz Past President of the European Society of Hypertension

Prof. Michel Burnier Treasurer of the Foundation of the European Society of Hypertension



The conference is intended only for persons authorized to prescribe drugs or pharmacists and for persons trading in medicinal products — legal basis. Act of 6 September 2001. Pharmaceutical Law (Journal of Laws from 2019, item 499, as amended).

SZCZEGÓŁY

PATRONAT MEDIALNY

PARTNER

tymed

🗮 ikamed.pl



Programme

Thursday, 25 April 2024

CONFERENCE ROOM

18:00-18:15 **Opening Ceremony**

18:15-19:00Invated lecture. Why (and when) is it worth to gender our
research (and how to do it well)?

Friday, 26 April 2024

CONFERENCE ROOM

08:30-10:10	Session 1: Pathophysiology of hypertension in women
08:30-08:55	Sex hormones and BP regulation
08:55-09:20	Salt and salt sensivity of BP in women
09:20-09:45	Endothelin and the RAAS in pre-eclampsia: what role?
09:45-10:10	Sex diffrences in gut microbiota composiotion
10:10-10:30	Coffee break
10:30-12:10	Session 2: Update on hypertension risk factors in women

10:30-10:50	Arterial fibromuscular dysplasia: why is it more frequent in women?
10:50-11:10	Polygenic risk scores for BP and hypertensive disorders of pregnancy
11:10-11:30	Endometriosis and risk of hypertension
11:30-11:50	Polycystic ovary syndrome: an unrecognized CV risk factor?
11:50-12:10	Sleep disturbances and risk of hypertension: are there specificites in women?
12:10-13:30	Lunch break
13:30-16:00	Session 3: Hypertension-mediated organ damages: are there gender differences? Gender differences in heart and vessels.
13:30-13:55	Left ventricular hypertrophy and atrial fibrillation
13:55-14:20	Arterial structure and function
14:20-14:45	BP variability
14:45-15:10	Validating BP-measuring devices: what about pregnancy (on-line)
15:10-15:35	Heart failure with preserved ejection fraction and AF
15:35-16:00	Assisted reproductive technologies and premature vasculr aging
16:00-16:20	Coffee break
16:20-17:50	Session 4: Hypertension-mediated organ damegaes: are there gender differences?

16:20-16:40	Gender differences in renal microcirculation
16:40-17:00	Gender, development and progression of CKD
17:00-17:20	Impaired ferility in women with CKD
17:20-17:35	Coronary heart disease management: what about gender differences?
17:35-17:50	Sex differences in hypertension and hypertensive phenotypes: the HELIUS study

Saturday, 27 April 2024

CONFERENCE ROOM

08:30-10:45	Session 5: Diagnosis and management of hypertension: are there gender differences?
08:30-08:50	Women perception of the risk of hypertension and CV diseases
08:50-09:10	Assisted reproductive therapies and risk of hypertansion
09:10-09:30	Lifestyle programs after menopasue: possible?
09:30-09:50	Monitoring women before, during and after pregnancy: the POPPY study
09:50-10:10	White coat hypertension: is the gemder difference real?
10:10-10:30	Gender ascpects of resistant and malignant hypertension
10:45-11:00	Coffee break

11:00-12:45	Session 5: Diagnosis and management of hypertension in women
11:00-11:20	Low percentage of women in clinical trials: what implications?
11:20-11:40	Assosciation of BP with CV complications according to gender: is the difference real?
11:40-12:00	RAS blockers in women with childbearing potential: how to handle?
12:00-12:20	Sex-differences in hypertension management: does it matter?
12:20-12:40	New data on women and hypertansion: what impact on future guidelines?
12:45-13:00	Discussion and closure of the meeting



